kwic
novel
novel
right
off
ON
37
1
100
500
strict
ELIZA cgi-bash version rev. 1.90
- Medical English LInking keywords finder for the PubMed Zipped Archive (ELIZA) -
return
kwic search for novel out of >500 occurrences
330250 occurrences (No.59 in the rank) during 5 years in the PubMed. [no cache] 500 found
--- ABSTRACT ---
--- ABSTRACT END ---
[frequency of next (right) word to novel]
330250 occurrences (No.59 in the rank) during 5 years in the PubMed. [no cache] 500 found
| 37) We reveal a novel mechanism linking EGFR and the membrane-spanning, cancer-promoting protein CDCP1 (CUB domain-containing protein 1). |
| PMID:24681947 DOI:10.1038/onc.2014.88 |
| 2015 Oncogene |
| * EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface. |
| - Many cancers are dependent on inappropriate activation of epidermal growth factor receptor (EGFR), and drugs targeting this receptor can improve patient survival, although benefits are generally short-lived. We reveal a novel mechanism linking EGFR and the membrane-spanning, cancer-promoting protein CDCP1 (CUB domain-containing protein 1). Under basal conditions, cell surface CDCP1 constitutively internalizes and undergoes palmitoylation-dependent degradation by a mechanism in which it is palmitoylated in at least one of its four cytoplasmic cysteines. This mechanism is functional in vivo as CDCP1 is elevated and palmitoylated in high-grade serous ovarian tumors. Interestingly, activation of the EGFR system with EGF inhibits proteasome-mediated, palmitoylation-dependent degradation of CDCP1, promoting recycling of CDCP1 to the cell surface where it is available to mediate its procancer effects. We also show that mechanisms inducing relocalization of CDCP1 to the cell surface, including disruption of its palmitoylation and EGF treatment, promote cell migration. Our data provide the first evidence that the EGFR system can function to increase the lifespan of a protein and also promote its recycling to the cell surface. This information may be useful for understanding mechanisms of resistance to EGFR therapies and assist in the design of treatments for EGFR-dependent cancers. |
[
right
kwic]
(1)22  therapeutic |
(17)3 mutation |
(33)2 approaches |
(49)2 information |
| (2)11 and |
(18)3 paradigm |
(34)2 autosomal |
(50)2 inhibitors |
| (3)8 mechanism |
(19)3 role |
(35)2 candidate |
(51)2 learning |
| (4)8 method |
(20)3 strain |
(36)2 cardiac |
(52)2 modulators |
| (5)7 approach |
(21)3 target |
(37)2 clinical |
(53)2 object |
| (6)7 mutations |
(22)3 targeted |
(38)2 compounds |
(54)2 oral |
| (7)6 therapies |
(23)3 targets |
(39)2 data |
(55)2 polymer |
| (8)5 technique |
(24)3 treatment |
(40)2 described |
(56)2 potent |
| (9)4 strategies |
(25)3 type |
(41)2 dual |
(57)2 prognostic |
| (10)4 strategy |
(26)3 words |
(42)2 electroporation |
(58)2 putative |
| (11)4 surgical |
(27)2 *null* | (43)2 finding |
(59)2 recombinants |
| (12)3 antibacterial |
(28)2 anti-tumor |
(44)2 findings |
(60)2 results |
| (13)3 drug |
(29)2 antibiotic |
(45)2 form |
(61)2 therapeutical |
| (14)3 homozygous |
(30)2 anticancer |
(46)2 genetic |
(62)2 titanium |
| (15)3 insights |
(31)2 application |
(47)2 imaging |
(63)2 treatments |
| (16)3 mechanisms |
(32)2 applications |
(48)2 in |
add keyword
--- WordNet output for novel ---